Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis
https://doi.org/10.21886/2219-8075-2018-9-1-17-22
Abstract
This review reviews the efficacy and safety of therapy with tyrosine kinase inhibitors and pyrphenidone in idiopathic pulmonary fibrosis. The results of randomized trials of recent years are described in detail. The efficacy of taking tyrosine kinase inhibitors at the following key research points is considered: the annual rate of decrease in vital capacity of the lung, a 6-minute walk test, the quality of life of the patient, and the frequency of exacerbations. Systematic literature search was carried out on the databases Scopus, Web of Science, MedLine, elibrary and others.
References
1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et all. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fi brosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL
2. Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fi bro-sis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Th er. 2015;9:6407-19. doi: 10.2147/ DDDT.S76648
3. Hutchinson J, Fogarty A, Hubbard R, McKeever T et all. Global incidence and mortality of idiopathic pulmonary fi brosis: a systematic review. Eur Respir J. 2015;46(3):795– 806. doi: 10.1183/09031936.00185114
4. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D et al. Incidence and prevalence of idiopathic pulmonary fi brosis: review of the literature. Eur Respir Rev. 2012;21(126):355-61. doi: 10.1183/09059180.00002512
5. Richeldi L, Rubin AS, Avdeev S, Udwadia ZF, Xu ZJ. Idiopathic pulmonary fi brosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015;13:237. doi: 10.1186/s12916-015-0495-0
6. Hinz B, Phan SH, Th annickal VJ, Prunotto M, Desmoulière A, Varga J et all. Recent developments in myofi broblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340-55. doi: 10.1016/j.aj-path.2012.02.004
7. Booth AJ, Hadley R, Cornett AM, Dreff s AA, Matthes SA, Tsui JL et.all. Acellular normal and fi brotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med. 2012;186(9):866-76. doi: 10.1164/ rccm.201204-0754OC
8. Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012;31(1-2):295-321. doi: 10.1007/s10555-012-9346-z
9. Leitinger B, Kwan AP. Th e discoidin domain receptor DDR2 is a receptor for type X collagen. Matrix Biol. 2006;25(6):355-64. DOI: 10.1016/j.matbio.2006.05.006
10. Maeyama M, Koga H, Selvendiran K, Yanagimoto C, Hanada S, Taniguchi E et all. Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition. Cancer. 2008;113(10):2823-31. doi: 10.1002/ cncr.23900
11. Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ et all. Eff ects of nintedanib on the mi-crovascular architecture in a lung fi brosis model. Angiogenesis. 2017;20(3):359-372. doi: 10.1007/s10456-017-9543-z
12. Sato S, Shinohara S, Hayashi S, Morizumi S, Abe S, Okazaki H et all. Anti-fi brotic effi cacy of nintedanib in pulmonary fi brosis via the inhibition of fi brocyte activity. Respir Res. 2017;18(1):172. doi: 10.1186/s12931-017-0654-2
13. Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fi brosis. Th er Adv Respir Dis. 2015;9(3):121-9. doi: 10.1177/1753465815579365
14. Zhao H , Bian H , Bu X, Zhang S Zhang P, Yu J et all. Targeting of Discoidin Domain Receptor 2 (DDR2) Prevents Myofi -broblast Activation and Neovessel Formation During Pulmonary Fibrosis. Mol Th er. 2016;24(10):1734-1744. doi: 10.1038/ mt.2016.109
15. Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C et all. Nintedanib inhibits macrophage activation and ameliorates vascular and fi brotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76(11):1941-1948. doi: 10.1136/annrheumdis-2016-210823
16. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P et all. Anti-fi brotic eff ects of nintedanib in lung fi broblasts derived from patients with idiopathic pulmonary fi brosis. Respir Res. 2014;15:157. doi: 10.1186/ s12931-014-0157-3
17. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Cos-tabel U et all. Effi cacy and safety of nintedanib in idiopathic pulmonary fi brosis. N Engl J Med. 2014;370(22):2071-82. doi: 10.1056/NEJMoa1402584
18. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG Effi cacy of a tyrosine kinase inhibitor in idiopathic pulmonary fi brosis. N Engl J Med. 2011;365(12):1079-87. doi: 10.1056/NEJMoa1103690
19. Raghu G , Wells AU , Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F et all. Eff ect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med. 2017;195(1):78-85. doi: 10.1164/ rccm.201602-0402OC
20. Cottin V. Th e safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fi brosis. Expert Opin Drug Saf. 2017;16(7):857-865. doi: 10.1080/14740338.2017.1338268
21. Kim KK, Sisson TH, Horowitz JC. Fibroblast growth factors and pulmonary fi brosis: it’s more complex than it sounds. J Pathol. 2017;241(1):6-9. doi: 10.1002/path.4825
22. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Th an-nickal VJ et al. Eff ects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fi brotic diseases. J Pharmacol Exp Th er. 2007;321(1):35-44
23. Huang Z, Li H, Zhang Q, Tan X, Lu F, Liu H et all. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fi brosis. Drug Des Devel Th er. 2015;9:4319-28. doi: 10.2147/DDDT.S83055
24. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et all. Antifi brotic action of pirfenidone and predniso-lone: diff erent eff ects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fi bro-sis. Eur J Pharmacol. 2008;590(1-3):400-8. doi: 10.1016/j. ejphar.2008.06.046
25. Liu Y, Lu F, Kang L, Wang Z, Wang Y. Pirfenidone attenuates bleomycin-induced pulmonary fi brosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulm Med. 2017;17(1):63. doi:
26. 1186/s12890-017-0405-7
27. Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S et all. Pirfenidone and nintedanib modulate properties of fi broblasts and myofi broblasts in idiopathic pulmonary fi brosis. Respir Res. 2016;17:14. doi: 10.1186/s12931-016-0328-5
28. Ley B, Swigris J, Day BM, Stauff er JL, Raimundo K, Chou W et all. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017;196(6):756-761. doi: 10.1164/rccm.201701-0091OC
29. Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK et all. Eff ect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fi brosis. Lancet Respir Med. 2017;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5
30. Hui Ren, MD, Kai Wang, MD, Hao Yang, PHD, and Lingyun Gao, MD. Effi cacy and adverse events of pirfenidone in treating idiopathic pulmonary fi brosis. Saudi Med J. 2017; 38(9): 889–894. doi: 10.15537/smj.2017.9.19349
31. Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD. Pirfenidone safety and adverse event management in idiopathic pulmonary fi brosis. Eur Respir Rev. 2017;26(146):170057. doi: 10.1183/16000617.0057-2017
Review
For citations:
Strel’tsov E.A. Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis. Medical Herald of the South of Russia. 2018;9(1):17-22. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-1-17-22
Views:
969
Email this article 